InvestorsHub Logo
Followers 18
Posts 646
Boards Moderated 0
Alias Born 05/19/2017

Re: None

Tuesday, 08/13/2019 12:52:02 PM

Tuesday, August 13, 2019 12:52:02 PM

Post# of 8511
Any other company have these results?

Analyses of one-year data showed a 59.6% reduction in the rate of serious adverse events (SAEs) diagnosed as pneumonia, confirmed via chest x-ray, that extended through the first year of life. Efficacy was 72.9% through the first 180 days of lile for x-ray-confirmed pneumonia SAEs associated with RSV detection.



Nope. Only Novavax.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NVAX News